Patrick Morton, DO
Family Medicine · Aventura, FLNPI 1578598702
Payments from drug & device makers
Across 341 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Novartis$1K
- Otsuka America Pharmaceutical, Inc.$468
- Lilly USA, LLC$434
- Amgen$367
- Pfizer$348
- plus $4K from 33 others
What the payments were for
- Food & beverage$7,803100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $1,640 |
| Novartis | 58 | $1,007 |
| Otsuka America Pharmaceutical, Inc. | 9 | $468 |
| Lilly USA, LLC | 26 | $434 |
| Amgen(2 entities) | 16 | $367 |
| Pfizer | 19 | $348 |
| Johnson & Johnson | 19 | $321 |
| Abbott | 7 | $296 |
| AstraZeneca | 15 | $279 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $264 |
| Heartflow, Inc. | 2 | $264 |
| GSK | 12 | $262 |
| Sunovion Pharmaceuticals Inc. | 12 | $238 |
| E.r. Squibb & Sons, L.L.C. | 4 | $188 |
| Neurocrine Biosciences, Inc. | 4 | $176 |
| Cleerly, Inc. | 1 | $166 |
| Amarin Pharma, Inc. | 8 | $150 |
| Aimmune Therapeutics, Inc. | 5 | $107 |
| Idorsia Pharmaceuticals US Inc | 4 | $91 |
| Merck | 5 | $83 |
| Exact Sciences | 3 | $72 |
| AbbVie(2 entities) | 4 | $66 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Scilex Pharmaceuticals Inc. | 1 | $60 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Sun Pharmaceutical Industries Inc. | 2 | $46 |
| Boehringer Ingelheim | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Insightec,inc | 1 | $30 |
| Bayer | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Linus Health, Inc. | 1 | $21 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| IBSA Pharma Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Gilead | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,803 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $113,281 |
| MounjaroTirzepatide | 80 | $87,169 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $52,070 |
| LinzessLinaclotide | 64 | $50,106 |
| JardianceEmpagliflozin | 75 | $48,287 |
| OzempicSemaglutide | 35 | $40,138 |
| XareltoRivaroxaban | 73 | $39,463 |
| VascepaIcosapent Ethyl | 113 | $39,455 |
| GemtesaVibegron | 106 | $31,829 |
| JanuviaSitagliptin Phosphate | 45 | $29,948 |
| FarxigaDapagliflozin Propanediol | 26 | $24,502 |
| TradjentaLinagliptin | 29 | $18,296 |
| RybelsusSemaglutide | 18 | $18,120 |
| Lactulose | 225 | $17,470 |
| EntrestoSacubitril/Valsartan | 17 | $17,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $348 | $113,281212 claims |
| Lilly USA, LLCMounjaro, Trulicity | $434 | $98,92892 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $66,584104 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $1,640 | $66,42179 claims |
| GileadBiktarvy | $14 | $52,07013 claims |
| Johnson & JohnsonXarelto, Procrit | $321 | $50,36586 claims |
| AbbVieLinzess | $66 | $50,10664 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $279 | $47,711101 claims |
| MerckJanuvia, Janumet | $83 | $34,61361 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $21 | $31,829106 claims |
| NovartisEntresto | $1,007 | $17,15417 claims |
| Aimmune Therapeutics, Inc.Zenpep | $107 | $15,84833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Aventura
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.